## Amendments to the Claims

The listing of claims will replace all prior versions, and listing of claims in the application.

- 1. (Original) A pharmaceutical composition which comprises a sodium channel blocker in combination with a selective serotonin uptake inhibitor.
- 2. (Original) A pharmaceutical composition according to claim 1, wherein the selective serotonin uptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, duloxetine, sertraline, escitalopram and citalopram.
- 3. (Original) A pharmaceutical composition according to claim 1, wherein the sodium channel blocker is selected from the group consisting of lamotrigine, crobenetine, oxcarbamazepine and phosphenyloin.
- 4. (Original) A pharmaceutical composition according to any of claims 1, 2 or 3, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine.
- 5. (Withdrawn) A pharmaceutical composition according to any of claims 1, 2 or 3, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine.
- 6. (Original) A pharmaceutical composition according to any of claims 1, 2 or 3, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine.
- 7. (Withdrawn) A pharmaceutical composition according to any of claims 1, 2 or 3, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine.

## 8-15. (Cancelled).

- 16. (Original) A method for the treatment and/or prevention of a disease occurring in a mammal, said disease involving chronic pain, epilepsy or deriving from disorders and/or injuries of the motor system, characterized in that a therapeutically effective amount of pharmaceutical composition comprising a sodium channel blocker and a selective serotonin uptake inhibitor is given to the subject in need of such treatment.
- 17. (Withdrawn) A method for the treatment and/or prevention of drug or alcohol addiction, incontinence of faeces and urine, inflammation, itching, intracranial edema, ischemia and/or subsequent damage caused by reperfusion or retinopathy, as a complication of glaucoma in mammals, characterized in that a therapeutically effective amount of pharmaceutical composition comprising a sodium channel blocker and selective serotonin uptake inhibitor is given to the subject in need of such treatment.
- 18. (Original) A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, duloxetine, sertraline, escitalopram and citalopram.
- 19. (Original) A method according to claim 16 or 17, wherein the sodium channel blocker is selected from the group consisting of lamotrigine, crobenetine, oxcarbamazepine and phosphenyloin.
- 20. (Original) A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is lamotrigine.
- 21. (Withdrawn) A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is fluoxetine and the sodium channel blocker is crobenetine.
- 22. (Original) A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is lamotrigine.

23. (Withdrawn) A method according to claim 16 or 17, wherein the selective serotonin uptake inhibitor is sertraline and the sodium channel blocker is crobenetine.